Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Adjuvant Pembrolizumab After Nephrectomy in Renal-Cell CarcinomaN. Engl. J. Med 2021 Aug 19;385(8)683-694, TK Choueiri, P Tomczak, SH Park, B Venugopal, T Ferguson, YH Chang, J Hajek, SN Symeonides, JL Lee, N Sarwar, A Thiery-Vuillemin, M Gross-Goupil, M Mahave, NB Haas, P Sawrycki, H Gurney, C Chevreau, B Melichar, E Kopyltsov, A Alva, JM Burke, G Doshi, D Topart, S Oudard, H Hammers, H Kitamura, J Bedke, RF Perini, P Zhang, K Imai, J Willemann-Rogerio, DI Quinn, T Powles
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.